Day One Biopharmaceuticals has entered into a Cooperative Research and Development Agreement with NCI’s Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program to expand therapeutic research opportunities using DAY101 (tovorafenib).
HOOKIPA Pharma Inc., a company developing a new class of immunotherapies based on its proprietary arenavirus platform, and Roche formed a strategic collaboration and license agreement to develop HB-700 for KRAS-mutated cancers, along with a second undisclosed novel arenaviral immunotherapy. This represents HOOKIPA’s first oncology licensing collaboration.
Jazz Pharmaceuticals plc and Zymeworks Inc.’s subsidiary, Zymeworks BC Inc., entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks’ zanidatamab across all indications in the U.S., Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.
The Bezos family has committed $710.5 million to Fred Hutchinson Cancer Center over the next 10 years—likely the largest single private contribution made to a cancer center in the U.S.
Earlier this week, The New England Journal of Medicine published the first results of the Pragmatic Nordic-European Initiative on Colorectal Cancer (NordICC) Trial of Colonoscopy, which was conducted in Poland, Norway, Sweden, and the Netherlands to measure the efficacy of colonoscopy in reducing colorectal cancer incidence and mortality.
“Doc, should I cancel my colonoscopy?”
The unprovoked war in Ukraine has raised increasing concerns of a nuclear escalation.
In the late 1960s, NCI received the modern-day equivalent of billions of dollars to establish a viral oncology program. At the time, the study of the role viruses played in cancer (or whether they played any role at all) was unknown. This could have been either a triumph or a huge and embarrassing waste of... […]
The Fred C. and Katherine B. Andersen Foundation of Bayport, MN, has made a $100 million multi-year commitment to support the expansion of Mayo Clinic’s proton beam facility in Rochester to nearly double appointment access for patients.
UC Davis Comprehensive Cancer Center has established a Center for Experimental Therapeutics in Cancer to accelerate promising cancer therapies from the lab to the bedside.
